Liquidia (NASDAQ:LQDA) Insider Sells $768,550.19 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 20,533 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $768,550.19. Following the completion of the transaction, the insider directly owned 154,514 shares in the company, valued at $5,783,459.02. The trade was a 11.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Scott Moomaw also recently made the following trade(s):

• On Monday, December 1st, Scott Moomaw sold 831 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total value of $26,749.89.

Liquidia Stock Performance

Shares of LQDA stock opened at $38.79 on Friday. The stock has a market cap of $3.37 billion, a PE ratio of -26.94, a price-to-earnings-growth ratio of 0.68 and a beta of 0.48. The stock has a 50-day moving average of $32.68 and a 200-day moving average of $25.77. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. Liquidia Corporation has a one year low of $11.26 and a one year high of $41.57.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm had revenue of $54.34 million during the quarter, compared to analysts’ expectations of $18.86 million. The business’s quarterly revenue was up 1106.7% on a year-over-year basis. As a group, sell-side analysts expect that Liquidia Corporation will post -1.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on LQDA shares. Raymond James Financial reaffirmed a “strong-buy” rating and set a $47.00 price objective on shares of Liquidia in a research note on Tuesday, November 4th. Wells Fargo & Company assumed coverage on Liquidia in a research report on Monday, October 20th. They set an “overweight” rating and a $31.00 price target on the stock. BTIG Research reiterated a “buy” rating and issued a $49.00 price objective on shares of Liquidia in a research report on Friday, January 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $39.67.

Hedge Funds Weigh In On Liquidia

A number of large investors have recently bought and sold shares of the company. SG Americas Securities LLC raised its holdings in shares of Liquidia by 46.7% in the fourth quarter. SG Americas Securities LLC now owns 54,696 shares of the company’s stock valued at $1,886,000 after purchasing an additional 17,407 shares during the last quarter. Insight Wealth Strategies LLC bought a new position in Liquidia in the fourth quarter valued at $4,891,000. Tudor Investment Corp ET AL acquired a new stake in Liquidia in the 3rd quarter valued at $1,536,000. FNY Investment Advisers LLC bought a new stake in Liquidia during the 3rd quarter worth about $34,000. Finally, Caxton Associates LLP acquired a new position in shares of Liquidia during the 3rd quarter worth about $389,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).